News | Proton Therapy | February 01, 2019

University of Oklahoma Cancer Center Begins First Proton Therapy Treatments

Stephenson Cancer Center is one of three locations in the world with Mevion’s S250i system with Hyperscan pencil beam scanning technology

University of Oklahoma Cancer Center Begins First Proton Therapy Treatments

February 1, 2019 — Home to the largest and most comprehensive radiation therapy program in Oklahoma, the Stephenson Cancer Center at OU (The University of Oklahoma) Medicine has commenced proton therapy treatments with the Mevion S250i Proton Therapy System with Hyperscan Pencil Beam Scanning. Cleared by the U.S. Food and Drug Administration (FDA) in 2017, Hyperscan improves on existing scanning capabilities to deliver conformal fields of therapeutic radiation to tumors faster with more precision.

“We are excited to offer our patients this advanced radiation therapy,” said Terence Herman, M.D., radiation oncologist at the Stephenson Cancer Center. “We provide a full range of treatment options, which ensures patients can stay in Oklahoma to receive the best possible care. Proton therapy is yet another important tool we can use in the fight against cancer, and the Mevion Hyperscan system provides a level of precision that far exceeds that of earlier, non-focused proton treatment techniques.”

As part of OU Medicine’s National Cancer Institute-designated cancer center, the single-room compact proton system is embedded directly into the radiation oncology department. This efficient approach enables the cancer center to share existing resources and give patients access to OU Medicine’s robust collection of cancer-fighting therapies under one roof.

OU Medicine anticipates using the new system to treat brain tumors, select head-and-neck tumors, abdominal tumors such as pancreatic cancer, some rare neural tumors, localized prostate cancer and essentially all tumors in pediatric patients. Several research projects are planned as well.

For more information: www.mevion.com

Related Content

Nearly 40 MRIdian-focused presentations will be part of the ASTRO Scientific Sessions
News | Magnetic Resonance Imaging (MRI) | October 26, 2020
October 26, 2020 — ViewRay, Inc. announced that the company's MRIdian Linac MRI-guided radiation therapy system will
Treating lung cancer patients with proton therapy may help reduce the risk of radiation-induced heart diseases, suggests a new study from Penn Medicine. In a retrospective trial of more than 200 patients, mini-strokes were significantly less common among patients who underwent proton therapy versus conventional photon-based radiation therapy. Proton therapy patients also experienced fewer heart attacks.
News | Proton Therapy | October 25, 2020
October 25, 2020 — Treating lung cancer patients with prot...
Radiation Oncology Orchestrator (IntelliSpace Radiation Oncology) and Practice Management can reduce the time from patient referral to the start of treatment by up to half
News | Radiation Oncology | October 25, 2020
October 25, 2020 —Philips, a global leader in health technology, will showcase its latest advances in ...
AI-powered premium large bore CT scanner offers industry’s largest bore and widest field-of-view
News | Computed Tomography (CT) | October 24, 2020
October 24, 2020 — An estimated 1.8 million new cancer cases will be diagnosed in the U.S.
The research evaluates the feasibility of biology-guided radiotherapy to treat metastatic cancer
News | Radiation Therapy | October 24, 2020
October 24, 2020 — ...
Be sure to register for the American Society for Radiation Oncology's (ASTRO) 62nd Annual Meeting, to be held October 24-28, 2020, via an interactive virtual platform. The meeting, Global Oncology: Radiation Therapy in a Changing World, will feature reports from the latest clinical trials; panels on global oncology, health disparities and the novel coronavirus; and an immersive attendee experience in a virtual convention center.
News | ASTRO | October 23, 2020
October 23, 2020 — Be sure to ...